Is Zealand Pharma (CPSE:ZEAL) Undervalued After Its Phase 3 Launch And CHMP Backing?

Zealand Pharma (CPSE:ZEAL) has moved back into focus after two pipeline milestones. The stock reacted to a new global Phase 3 obesity program for petrelintide and a positive European opinion on Zeydovio for short bowel syndrome.

Despite the fresh pipeline momentum, Zealand Pharma’s 1 month share price return is down 12.45%, contributing to a year to date share price decline of 38.88%. However, the 5 year total shareholder return of 38.80% suggests longer term holders have still seen a positive payoff.

Scan biopharma pipelines beyond Zealand Pharma and discover other treatment-focused stories at a similar inflection point by reviewing the hand picked 132 healthcare AI stocks.

The recent slump in Zealand Pharma after major pipeline news puts a clear choice in front of you: treat the weakness as an early entry or wait for more certainty around what the current valuation already implies.

Most Popular Narrative: 35% Undervalued

On the numbers, the most followed narrative values Zealand Pharma at DKK 433.36 per share versus a last close of DKK 281.20. This puts the current obesity and gastrointestinal pipeline into sharp focus.

The alliance with Roche for petrelintide significantly derisks commercialization and broadens access to manufacturing and distribution scale, positioning Zealand to capitalize on the global surge in obesity and metabolic disorder prevalence, a trend expected to underpin sustained long term demand and topline expansion.

See why 27 investors see Zealand Pharma as 35% undervalued.

Result: Fair Value of DKK433.36 (UNDERVALUED)

Still, two pressure points could flip the Zealand Pharma story: clinical setbacks on petrelintide or survodutide, and slower than expected obesity market adoption.

Find out about the key risks to this Zealand Pharma narrative.

Next Steps

Investor sentiment around Zealand Pharma appears mixed after these updates. Consider both sides of the thesis while the narrative is still fresh and review the 1 key reward and 1 important warning sign.

Looking for more investment ideas beyond Zealand Pharma?

If Zealand Pharma has your attention, do not stop here. Use the screener to spot other opportunities before the rest of the market catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com